Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Comparative Study of Surgical Splenectomy, Partial Splenic Embolization, and High-Intensity Focused Ultrasound for Hypersplenism.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2016
Same author

Secure and Privacy-Preserving Body Sensor Data Collection and Query Scheme.

Sensors (Basel, Switzerland)·2016
Same author

The effects of haze on dew quality in the urban ecosystem of Changchun, Jilin Province, China.

Environmental monitoring and assessment·2016
Same author

Correction: Targeted Next-Generation Sequencing for Clinical Diagnosis of 561 Mendelian Diseases.

PloS one·2016
Same author

DDQ-Mediated Oxidative Radical Cycloisomerization of 1,5-Diynols: Regioselective Synthesis of Benzo[b]fluorenones under Metal-Free Conditions.

Organic letters·2016
Same author

Correction: Feasibility of Elective Nodal Irradiation (ENI) and Involved Field Irradiation (IFI) in Radiotherapy for the Elderly Patients (Aged ≥ 70 Years) with Esophageal Squamous Cell Cancer: A Retrospective Analysis from a Single Institute.

PloS one·2016

Related Experiment Video

Updated: Jul 8, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

390

Celastrol inhibits platelet function and thrombus formation.

Xiaoqian Li1, Jie Zhang1, Yingying Li1

  • 1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China.

Biochemical and Biophysical Research Communications
|December 13, 2023
PubMed
Summary

Celastrol significantly inhibits platelet aggregation, granule release, and clot formation. This compound may offer a novel therapeutic approach for managing thrombotic diseases.

Keywords:
Calcium mobilizationCelastrolHemostasisPlateletsThrombosis

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

897

Related Experiment Videos

Last Updated: Jul 8, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

390
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

897

Area of Science:

  • Pharmacology
  • Hematology
  • Biochemistry

Background:

  • Celastrol, a pentacyclic triterpenoid from Tripterygium wilfordii, possesses known anti-inflammatory and anti-tumor activities.
  • The effect of Celastrol on platelet function and its potential role in thrombosis have not been previously investigated.

Purpose of the Study:

  • To investigate the modulatory effects of Celastrol on human platelet function.
  • To evaluate the in vivo impact of Celastrol on hemostasis and thrombosis.

Main Methods:

  • Human platelets were isolated and treated with varying concentrations of Celastrol (0-5 μM) to assess aggregation, granule secretion, spreading, clot retraction, and calcium mobilization.
  • In vivo studies involved administering Celastrol (2 mg/kg) to mice to evaluate tail bleeding time and thrombosis formation.

Main Results:

  • Celastrol dose-dependently inhibited platelet aggregation and secretion induced by collagen-related peptide (CRP) or thrombin.
  • Platelet spreading and clot retraction were significantly reduced by Celastrol treatment.
  • In vivo, Celastrol administration prolonged bleeding time and attenuated arterial and venous thrombosis.
  • Celastrol significantly decreased intracellular calcium mobilization in platelets.

Conclusions:

  • Celastrol demonstrates potent anti-platelet activity, inhibiting key functions involved in thrombosis.
  • These findings suggest Celastrol's potential as a therapeutic agent for thrombotic disorders.